INTRODUCTION
Respiratory syncytial virus (RSV) is the most frequent cause of lower respiratory tract infection (LRTI) in young children and by the age of two years, 80% of children have encountered the infection. 1, 2 Risk factors pre-disposing to severe RSV-related lower respiratory tract infection (LRTI) include prematurity, bronchopulmonary dysplasia, congenital heart disease and immunodeficiencies. [3] [4] [5] [6] In patients with cystic fibrosis (CF) viral infections have been shown to be associated with increased hospitalization rates and decline in pulmonary function, resulting in short-term and long-term morbidity. [7] [8] [9] [10] A marked inflammatory response to RSV infection in patients with CF has been observed, with reported hospitalization rates up to 14.6%. 11, 12 These infants often have a prolonged hospital admission and some studies have noted a greater decline in lung function among infants with CF with a history of RSV-related hospitalization than those who did not require admission. 12 No vaccine against RSV is currently available and treatment of RSV bronchiolitis is largely symptomatic. The monoclonal antibody Palivizumab is the only preventative therapy. It has proven efficacy and safety against RSV in randomized controlled trials involving preterm infants < 35 weeks' gestational age, children aged < 2 years with severe chronic lung disease and haemodynamically significant congenital cardiac disease. 13, 14 Use of Palivizumab in the CF population is not widespread practice. Recent surveys revealed its use in only 8.8% of UK centres, with higher usage within North American centres, 75 % in the US and 60% in Canada. 15, 16 The recent Cochrane review by Robinson et al. identified only one randomised control trial on the use of palivizumab for prophylaxis against RSV infection in CF. This study found admission rates were not decreased, however RSV incidence was very small and the review determined that evidence is insufficient to draw conclusions on the efficacy and safety of palivizumab in this group. 13, 17 Few studies have investigated the use of palivizumab therapy to prevent RSV in CF. Most are non-randomised, involving small numbers of patients with limited follow-up periods and inconclusive results. 11, 12 One US study in a large CF population found potential benefits to using palivizumab however results were inconclusive due to the small event rate of RSVrelated hospitalization. 18 A recent meta-analysis has found that prophylactic treatment with palivizumab may be effective in reducing hospital admission rates due to RSV-related LRTIs. 19 In Northern Ireland screening for cystic fibrosis has taken place since the 1980s. Early identification of affected infants enabled the introduction of routine palivizumab administration for since 2002. This was given to all CF infants at the start of their first RSV season regardless of age with further doses in their second season for high-risk infants or those less than 1-year-old This population therefore provides a unique opportunity to examine the effect of palivizumab use in CF patients on rates of hospitalisation secondary to RSV-related LRTI, as well as long term follow-up of its impact on lung function and bacterial colonization rates.
METHODS

Design
We undertook a retrospective audit of outcomes for children born during the period from Only children diagnosed via the neonatal screening program were included. Those born outside of Northern Ireland and therefore not diagnosed on screening were excluded as they could not have been offered timely palivizumab.
Data Collection
All patients were identified from the patient registry at the Northern Ireland Regional Parental consent is obtained as standard for patient data to be included in a national online database that may be used anonymously for audit and research purposes. This audit was conducted as part of a hospital service evaluation and therefore ethical approval was not required.
Definitions
Genotype was defined according to the presence of delta F508 deletion and recorded for each patient as homozygous F508del mutation, heterozygous F508del mutation or other (no Presence of bacterial colonisation was identified from individual bacteriology result records.
All bacteriology samples from the unit are processed using standardised techniques in the microbiology laboratory at the Royal Victoria Hospital, Belfast. Cough swabs are taken at least three monthly from birth as part of the routine care of every CF patient at the centre and more frequently in periods of illness during which cough swabs and/or sputum swabs will additionally be taken. P. aeruginosa chronicity was defined as having > 3 discrete P.
aeruginosa positive nasal/cough swabs or sputum culture results within a one year period.
Health economic evaluation
A basic health economic evaluation was conducted to compare costs of palivizumab prophylaxis versus costs saved. Administration of palivizumab occurred during routine clinics at the Northern Ireland Regional Paediatric Cystic table) . These data were used to calculate total costs for each cohort. No discounting of costs was applied, as the time horizon was less than 1 year.
Statistical analyses
Descriptive data is summarised as means (standard deviations, SD) or medians (interquartile ranges). Children receiving palivizumab (those born after routine introduction in 2002) were compared to those who did not receive palivizumab (those born before routine introduction). Comparisons were made between cohorts using data collected aged 6 years. 
RESULTS
Subjects
A total of 98 cystic fibrosis patients were identified as being born during the defined period, 6
were excluded due to being born outside Northern Ireland. All patients in the palivizumab recipient cohort (those born after 2002, n=45) received palivizumab in their first year of life before the onset of the RSV season. The average age at first dose of palivizumab was 99.4
days old and the average number of doses received was 5.1 (SD= 2.0).
A greater proportion of males (p=0.031) were noted in the palivizumab non-recipient cohort (table 1) . Statistically similar numbers of CF affected first degree relatives (p=0.14) were observed in both cohorts, with similar CF genetic mutation classes observed (p= 0.45).
RSV-Positive Hospitalizations
The overall RSV-positive hospitalization rate is 13%. Relative risk of RSV infection in palivizumab non-recipients versus recipients is 4.78 (95% CI: 1.1 -20.7). Those who received palivizumab were significantly less likely to be admitted to hospital for RSV-related LRTI than non-palivizumab recipients: 2 / 45 versus 10/47, p=0.027 (median duration of hospital stay 3 versus 10 days).
For one patient in the palivizumab non-recipient cohort data was not available for duration of hospital stay secondary to RSV-related LRTI.
Growth parameters
No significant difference was noted for weight, height or BMI at age 6 years between palivizumab and non-palivizumab recipients (table 2) .
Lung function testing
No significant difference was evident between FEV1 (% of predicted value) at 6 years of age between cohorts ( Table 2) . No difference was noted in FEV1 at 6 years of age in patients with RSV-related hospital admission versus non-admission regardless of palivizumab status.
Bacterial colonisation rates
Of note, there was a significant difference in the median time to first isolate of PA between cohorts with a significantly earlier time to first isolate noted in the palivizumab recipient cohort. Using survival analysis modelling (Figure 1 ), the median time to P. aeruginosa first isolate in the palivizumab non-recipient cohort was 96 months versus 57 months in the palivizumab recipient cohort (Wilcoxon test, p 0.025).
The risk ratio of PA first isolate in males versus females (irrespective of palivizumab status) was 2.05, p 0.006. PA first acquisition by genotype is illustrated in figure 2 . The relative risk of PA first isolate for homozygous F508del versus other genetic mutations was 4.5 (p <0.001) and overall, males with homozygous F508del mutation had the highest risk of first PA acquisition irrespective of palivizumab status.
Having adjusted for gender and genotype, the relative risk of PA first isolate during the study time period in the palivizumab recipient cohort versus non-recipient cohort was 2.5, p 0.001 (95% CI: 1.44 -4.2).
The separation in survival curves is noted to occur from 2 months of age. Two infants noted to have PA acquisition at 2 months of age both received palivizumab at 24 days of age.
Importantly, no significant difference was noted for chronic P. aeruginosa infection rates at 6 years old between cohorts. Only 3 patients had chronic P. aeruginosa infection aged 6 years in the palivizumab non-recipient cohort and 2 patients in the palivizumab recipient cohort. 
Health economic evaluation
DISCUSSION
To our knowledge, this is the first long-term follow up of CF infants following palivizumab prophylaxis for RSV. We found a significant reduction in RSV-related hospitalisation in patients who received prophylactic palivizumab versus those who did not. However, in view of the small numbers included in this study it is difficult to make robust statements on this outcome. A recent study in Limerick, Ireland, did not demonstrate any significant difference in outcomes with palivizumab use, although notably, this study was not conducted in a screened population. 23 Our study represents a unique opportunity to present outcomes in a screened population where care is provided by a single team delivering standardised care over the duration of the period studied.
Reduced lung function following RSV infection in CF patients has been noted in previous studies at follow-up times less than one year. 12 Our findings did not demonstrate any significant difference in lung function at 6 years between cohorts despite reduced RSV infection rates with use of palivizumab. A possible explanation for this is that any deterioration in lung function may be a short term effect, not persisting into early childhood.
Of note, FEV1 may not be the most sensitive measure of lung damage in CF patients and is often preserved in this age group. Alternative measures of lung function may prove more useful in this context. The lung clearance index (LCI), for example, reflects abnormalities of the small airways and therefore detects earlier signs of lung injury in CF which may be different between groups at this early age. 24 However, at present, alternative lung function measurements such as LCI are not undertaken at our centre and were therefore unavailable for comparison.
Limited data exists on other important outcomes in relation to palivizumab prophylaxis in CF patients, particularly in relation to bacterial colonisation. The interaction of bacterial colonisation and viral infection in CF is not fully understood. It has been extensively demonstrated that lung function deteriorates significantly after colonisation by PA. 22 Enhanced bacterial adherence to virus infected cells may facilitate bacterial colonisation in CF patients. 225 60-68% of new bacterial colonisation cases are detected during the viral season and 85% of new PA colonisations occur within three weeks of a viral infection. 226, 27 Furthermore, human airway epithelial cells infected with RSV demonstrate enhanced binding of several species of bacteria and one study has detected a rise in antipseudomonal antibodies following viral infection in patients suffering from CF, with the strongest association after RSV infection. 28 Our findings did unexpectedly demonstrate a significant decrease in the age of first isolation of PA in patients who had received palivizumab in comparison to those who did not. These surprising results are apparently contradictory to the assumption that prevention of RSVrelated LRTIs with palivizumab will lead to decreased rates of PA colonisation. Although we cannot fully exclude this we do not believe that these results can be explained by altered or improved diagnostic tests as there has been no change in how these are performed throughout the observed study period in our clinic.
It is important to emphasise that our results found low overall chronic PA colonization rates at age six years and did not show any significant difference between cohorts. This is not surprising given that aggressive eradication regimes are routinely implemented following first The cost comparison highlights the higher costs associated with a program delivering palivizumab as a prophylaxis to CF patients, from a payer perspective. This aligns with previous findings in high-risk paediatric populations, where the high costs of administering the drug were greater than the reduction in costs of hospitalisations for RSV-related LRTIs. 27, 28 However, caution is needed in the interpretation of this partial economic evaluation. While it is likely that an unknown confounding factor may account for the apparent earlier PA acquisition in palivizumab recipients the difference merits further consideration. Given that many countries have commenced routine CF screening, timely palivizumab prophylaxis is now an option. This is a very costly therapy that will necessitate additional resources and therefore we strongly believe that a double blind randomised control trial is required with longer term follow up before this therapy becomes introduced to standard care.
CONCLUSION
This present study demonstrates reduced RSV-related LRTI hospitalisation in infants with CF who receive palivizumab prophylaxis. Of note, the partial cost analysis highlights the higher costs associated with palivizumab as a prophylaxis to CF patients compared to savings from reduced hospitalisations. Importantly, we observed an unexpected and potentially worrying trend towards earlier P. aeruginosa first acquisition in patients with CF who receive palivizumab prophylaxis. We do highlight this is a sub-optimal study design and therefore no compelling conclusions can be drawn, however we add to the call for an urgent new clinical trial to clarify the efficacy and safety of palivizumab in infants with cystic fibrosis.
